NEW YORK (GenomeWeb News) – Health Discovery Corporation said this week that Stephen Barnhill has resigned from the CEO position, although he will continue to serve as a consultant and as interim CEO until a replacement is hired and brought up to speed on the firm's technologies and products.
Rheonix has named Bill Colston to its board of directors, the Ithaca, NY-based molecular testing company said this week. Colston is the former CEO of QuantaLife, which was acquired by Bio-Rad Laboratories in 2011. As QuantaLife CEO, Colston grew the company from four founders in 2008 to more than 60 employees by 2011. Before founding QuantaLife in 2008, Colston had a 19-year career at Lawrence Livermore National Laboratory, advancing from scientist to program manager directing a $160 million annual budget and 400 employees.
BioFire Diagnostics said this week that it has appointed Herm Rosenman to its board of directors and chairman of the audit committee. Rosenman was senior vice president and CFO of Gen-Probe from 2001 until its recent acquisition by Hologic. Prior to joining Gen-Probe, Rosenman served as CEO of two Nasdaq-listed companies, served on the boards of multiple healthcare companies, and was a partner at Coopers & Lybrand (now PricewaterhouseCoopers).
Rebecca Chambers has joined Illumina as senior director of investor relations, the San Diego-based genetic analysis tools firm said during its third-quarter conference call this week. Chambers joins the firm from Myriad Genetics, where she was head of investor relations and corporate communications.
Ross Fitzgerald, who is a group leader at the Roslin Institute, has been named chair in molecular biology at the University of Edinburgh. Fitzgerald launched his research career at the University of Dublin, Trinity College, and he joined Roslin in 2008, where he since has been named a senior lecturer and reader. His research interests have focused on the evolution of staphylococci populations, and it is aimed at developing translational discoveries for use in diagnostic, therapeutic, and vaccine-based methods for controlling staph infections.
GnuBio has promoted Susie Truong Harborth to chief financial officer. She has been at the company since it was founded. Previously, she held senior management positions at Cequent Pharmaceuticals, which was acquired by Marina Biotech. She is also a cofounder of BioInnovation and worked at investment bank Leerink Swann.
Philip Bourne has stepped down from his position as editor in chief of PLOS Computational Biology, a role he has held for seven years.
Bourne, who was also one of the founders of the journal, said in an editorial that he will still be involved with the journal — he will focus on special projects. He is a professor with the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego. He is also associate director of the RCSB Protein Data Bank and an adjunct professor at the Sanford Burnham Institute.
Ruth Nussinov, who has served as the journal’s deputy editor in chief since October 2008, will take over Bourne’s responsibilities at the journal. She is a professor in the department of human genetics at Tel Aviv University’s School of Medicine and a senior principal scientist and principal investigator at the National Cancer Institute.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.